SEC Form 4 · accession 0000899243-19-006308
Global Blood Therapeutics, Inc. · GBT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lesley Ann Calhoun
Officer — See Remarks
Period of report
Mar 1, 2019
Accepted (ET)
Mar 5, 2019 · 8:48 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001629137
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 1, 2019 | M | 300 | — | A | 1,332 | D | |
| Common StockF2 | Mar 1, 2019 | F | 104 | $53.48 | D | 1,228 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F3 | — | Mar 1, 2019 | M | 300 | D | — | — | Common Stock | 300 | 1,200 | D |
Explanation of responses
- F1Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
- F2Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 300 shares of Common Stock underlying the Reporting Person's RSUs.
- F3The RSUs vest in eight semiannual installments after March 1, 2017 until fully vested on March 1, 2021, subject to the Reporting Person's continuous service with the Issuer. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
Remarks
Vice President, Finance and Principal Accounting Officer